The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 31.25
Bid: 31.00
Ask: 31.50
Change: 0.25 (0.81%)
Spread: 0.50 (1.613%)
Open: 31.25
High: 31.30
Low: 31.25
Prev. Close: 31.00
DUKE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of EGM and Issue of £17.5 million of Equity

30 Oct 2019 13:55

RNS Number : 6704R
Duke Royalty Limited
30 October 2019
 

 

 

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")

Result of EGM and Issue of £17.5 million of Equity

Duke Royalty Limited (AIM: DUKE), a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad, announces that the Extraordinary Resolution put to Shareholders in connection with the Fundraising was duly passed at the General Meeting held earlier today. The voting results of the General Meeting will be available to view on the Company's website shortly at www.dukeroyalty.com.

The Company is pleased to confirm it has raised an additional £892,287 by way of Open Offer, as it received final valid applications from Qualifying Shareholders in respect of 2,027,925 Open Offer Shares including applications under the Excess Application Facility.

Accordingly, the Company has raised a total of approximately £17.45 million (before expenses) via the Fundraising, following the issue and allotment of 39,667,899 new ordinary shares (the Fundraising Shares"), comprising 36,591,000 Placing Shares, 2,027,925 Open Offer Shares and 1,048,974 Retail Offer Shares. An application has been made for the Fundraising Shares to be admitted to trading on AIM (Admission), which is expected to take place at 8.00 a.m. on 31 October 2019.

Directors' participation in the Fundraise

Name

No. of existing Ordinary Shares

No. of Placing Shares

Total holding

Percentage ofenlarged issuedshare capitalfollowingAdmission

Neil Johnson (1)

3,507,193

142,807

3,650,000

1.52

Charles Cannon-Brookes (2)

5,400,000

 

156,693

5,556,693

2.32

 

Justin Cochrane

740,000

75,000

815,000

0.34

 

(1) Of these, prior to the Fundraising 1,800,193 Ordinary Shares are legally owned by Abingdon Capital Corporation ("Abingdon"). Abingdon has not subscribed for any New Shares in the Fundraising. Mr Johnson is Abingdon's sole voting shareholder. Following the issue of New Shares, Abingdon will legally own 1,800,193 Ordinary Shares on Admission. Mr Johnson has subscribed in his own name for 142,807 New Shares, representing £62,835 in the Fundraising.

(2) Of these, prior to the Fundraising 2,500,000 Ordinary Shares are legally owned by Arlington Group Asset Management ("Arlington"). Arlington has subscribed for 156,693 New Shares, representing £68,945 in the Fundraising. Mr Cannon-Brookes is the investment director of Arlington and holds 40.27 percent of the voting shares of Arlington. Following the issue of New Shares, Arlington will legally own 2,656,693 Ordinary Shares on Admission.

Neil Johnson, CEO of Duke Royalty, said:

"We would like to thank our shareholders for the strong show of support in the Open Offer as well as welcome new investors onto our register as a result of the institutional Placing and Retail Offer. The strong uptake we have experienced through this Open Offer is very pleasing and shows continued support for our strategy to become the leading corporate royalty provider in the UK and Europe. With numerous follow-on and new royalty opportunities in the pipeline, we look forward to deploying the additional capital and in turn, enhancing the robust, predictable, long term returns we have demonstrated for shareholders."

Following Admission, the Company's issued ordinary share capital will comprise 239,540,358 ordinary shares of nil par value, of which none are held in treasury. The above figure of 239,540,358 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise defined, capitalised terms shall have the meaning as those set out in the 'Definitions' section of the announcement issued by the Company on 4 October 2019.

 

For further information, please contact www.dukeroyalty.com, or contact:

 

Duke Royalty Limited

Neil Johnson / Charlie Cannon Brookes

 

+44 (0) 1481 741 240

Cenkos Securities plc 

(Nominated Adviser and Broker)

 

Julian Morse / Michael Johnson / Stephen Keys / Callum Davidson

+44 (0) 207 397 8900

Edison Investment Research Limited

 

Elliot Berstock

+44 (0) 20 3077 5700

Newgate Communications

(PR)

Elisabeth Cowell/ Ian Silvera/ Megan Kovach

+44 (0) 20 3757 6882

PrimaryBid Limited

Kieran D'Silva

+44 (0) 207 491 6519

 

About Duke Royalty

 

Duke Royalty Limited provides alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad. Duke Royalty's experienced team provide financing solutions to private companies that are in need of capital but whose owners wish to maintain equity control of their business. Duke Royalty's royalty investments are intended to provide robust, stable, long term returns to its shareholders. Duke Royalty is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

**ENDS**

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCMMBJTMBAJBTL
Date   Source Headline
3rd Apr 20247:00 amRNSFollow-On Investment into Existing Capital Partner
2nd Apr 20247:00 amRNSNew Capital Partner - Integrum Care
28th Mar 20247:00 amRNSTrading and Operational Update
21st Mar 20247:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20247:00 amRNSSuccessful Exit of Investment in Fabrikat
6th Mar 20247:00 amRNSSuccessful Exit of Investment
4th Mar 20247:00 amRNSIncreased Equity Stake in United Glass Group
21st Feb 202411:57 amRNSName Change Effective
20th Feb 202412:08 pmRNSResult of General Meeting & Change of Name
5th Feb 20247:00 amRNSProposed Change of Name, Website and Messaging
29th Dec 20237:00 amRNSTrading Update and Follow-on Investment
19th Dec 20237:00 amRNSInterim Dividend and Dividend Declaration
29th Nov 20237:00 amRNSUpdate re. Change of Name of Nominated Adviser
22nd Nov 20237:00 amRNSFinancial Year 2024 Interim Results
21st Sep 20237:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20237:00 amRNSTrading Update
2nd Aug 20234:51 pmRNSResult of Annual General Meeting
31st Jul 20237:00 amRNSNew Royalty Agreement
28th Jul 20237:00 amRNSDirector/PDMR Dealings
20th Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
4th Jul 20237:00 amRNSFinal Results for the year ended 31 March 2023
3rd Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
26th Jun 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
15th Jun 20237:00 amRNSInterim Dividend and Dividend Declaration
9th Jun 20237:00 amRNSNotice of Results
1st Jun 20237:00 amRNSTrading Update
25th May 20237:00 amRNSDirectors' Dealings
24th May 20237:00 amRNSSuccessful Exit of Investment in Royalty Partner
22nd Mar 20237:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20237:00 amRNSNew Royalty Agreement
3rd Mar 20237:00 amRNSTrading Update
21st Feb 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
16th Jan 20237:00 amRNSClosing of New Credit Facility
15th Dec 20223:35 pmRNSInterim Dividend and Dividend Declaration
13th Dec 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
12th Dec 20227:00 amRNSRefinance and Upsize of Credit Facility
1st Dec 20227:01 amRNSTrading Update
1st Dec 20227:00 amRNS2023 Interim Results
29th Nov 202212:38 pmRNSResult of Annual General Meeting
25th Nov 20227:00 amRNSNew Royalty Agreement
14th Nov 20227:00 amRNSNotice of AGM and Notice of Interim Results
14th Oct 20227:00 amRNSPSAs, Issue of Equity & Director/PDMR Dealings
22nd Sep 20227:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20229:09 amRNSPublication of Annual Report & Accounts
9th Sep 20227:00 amRNSPostponement of Presentation
8th Sep 20227:00 amRNSFinal Results for the year ended 31 March 2022
31st Aug 20225:04 pmRNSHolding(s) in Company
30th Aug 20223:07 pmRNSHolding(s) in Company
5th Aug 20227:00 amRNSNotice of Results and Presentations
4th Aug 20227:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.